Morning, folks. A bumper deals upate last week as I was out of the office last week. Here are the top headlines I found across medical devices and biotech.
➡️ Granite Bio is ready to rock ‘n’ roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting several autoimmune diseases.
➡️Bayer is boosting its precision oncology efforts with a molecular database from health tech firm ConcertAI.
➡️Ypsomed is now fully exiting the diabetes care business with a plan to trade its insulin pump development arm and remaining subsidiaries to a new Swiss medtech, TecMed, in a deal worth up to $512mn.
➡️Biolinq has raised $100mn in venture capital financing to help complete the development of its wearable glucose biosensor—proceeds the company said would help set up its commercial efforts while it prepares submissions for U.S. regulatory approval.
➡️Etiome emerges with $50M from Flagship Pioneering and goal of preempting disease
➡️Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs, inline for $200m
➡️Field Medical raises $40M for PFA in ventricular tachycardia
➡️Barcelona-based Oryzon Genomics, SA, a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion has completed an oversubscribed €30m
➡️Imaging provider RadNet aims to acquire iCad and its artificial-intelligence-powered mammography software—with plans to fold them into its DeepHealth subsidiary.
➡️Cipher Surgical, a leading innovator in laparoscopic surgical technology, announced the successful completion of a $10mn Series A funding round.
➡️Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted medicines in the autoimmune disease space, worth up to $765m
➡️Grove Biopharma, a Chicago, IL-based biotechnology company, raised $30M in Series A funding. The company intends to use the funds to further advance its platform and drive its lead oncology programs towards
➡️German cancer antibody biotech Veraxa eyes SPAC as route to Nasdaq, valuing them at a potential $1.3bn
➡️VelaVigo Bio has landed its second deal in six months, offloading ex-China rights to a bispecific to Ollin Biosciences for up to $440mn.
➡️Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with little-known U.S. AI research biotech Earendil Labs in a pact that could be worth up to $1.8bn.
➡️The Netherlands has set itself an ambitious goal: to be among the global leaders in biotechnology by 2040. This vision is backed by an initial commitment of €1.3bn in funding.